

# 2016-2020 New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape

https://marketpublishers.com/r/297475E941EEN.html

Date: March 2016

Pages: 620

Price: US\$ 7,840.00 (Single User License)

ID: 297475E941EEN

# **Abstracts**

Complete report \$9,800. DataPack (test volumes, sales forecasts, supplier shares) \$6,400.

VPGMarketResearch. com's new report is a study of the major business opportunities emerging in the U. S. cancer diagnostics market during the nextfive years. The report examines trends in the U. S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

#### Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

#### **U. S. Market Overview**

Five-year test volume and sales projections.



Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Estimated universe of laboratories performing cancer diagnostic testing.

Cancer statistics, etiology and recent developments.

## **Business Opportunities and Strategic Recommendations**

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

## **Over 200 Current and Emerging Cancer Diagnostic Test**

**Biochemical Markers** 

Oncogenes

**Growth Factors** 

Hormones

**Colony Stimulating Factors** 

Lymphokines

Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27. 29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen



Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

#### **Supplier Shares, Sales and Volume Forecasts**

Sales and market shares of major cancer diagnostic product suppliers by individual test.

Five-year test volume and sales forecasts for major tumor markers by market segment, including:

Hospitals

Commercial/Private Laboratories

Physician Offices/Group Practices

**Cancer Clinics** 

#### Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

## **Technology Assessment**

Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.



Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. **Competitive**Strategies

Strategic assessments ofmajor suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Correlogic Systems/Vermillion

Abbott
AdnaGen/Alere
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid



Decode Genetics
Diadexus
Diagnocure
DiaSorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/Gen-Probe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho-Clinical Diagnostics



Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Thermo Fisher
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zilla



Contains 620 pages and 103 tables



## **Contents**

#### I. INTRODUCTION

## **II. Major Product Development Opportunities**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

## III. Design Criteria for Decentralized Testing Products

#### IV. Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
  - 1. MARKETING APPROACHES
  - 2. PRODUCT COMPLEXITY
  - 3. CUSTOMER PREFERENCE
  - 4. ESTABLISHED SUPPLIERS
  - 5. EMERGING SUPPLIERS
  - 6. MAJOR TYPES OF DISTRIBUTORS
  - 7. MARKET SEGMENTATION FACTOR

## V. Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

## VI. Worldwide Market and Technology Overview



- A. Cancer Statistics and Etiology
  - 1. BREAST CANCER
  - 2. LUNG CANCER
  - 3. COLON AND RECTUM CANCER
  - 4. PROSTATE CANCER
  - 5. STOMACH CANCER
  - 6. LEUKEMIA
  - 7. LYMPHOMA
  - 8. ORAL CANCER
  - 9. SKIN CANCER
  - 10. UTERINE CANCER
  - 11. OVARIAN CANCER
  - 12. BLADDER CANCER
- B. Major Current And Emerging Cancer Diagnostic Tests
  - 1. INTRODUCTION
  - 2. TUMOR MARKER CLASSIFICATION
  - 3. ACTH
  - 4. ALPHA-FETOPROTEIN (AFP)
  - 5. BETA-2 MICROGLOBULIN
  - 6. CA 15-3/27.29
  - 7. CA 19-9
  - 8. CA-125
  - 9. CALCITONIN
  - 10. CARCINOEMBRIONIC ANTIGEN (CEA)
  - 11. ESTROGEN AND PROGESTERONE RECEPTORS
  - 12. FERRITIN
  - 13. GASTRIN
  - 14. HUMAN CHORIONIC GONADOTROPIN (HCG)
  - 15. INSULIN
  - 16. NSE
  - 17. OCCULT BLOOD
  - 18. PAP SMEAR/HPV
  - 19. PROSTATIC ACID PHOSPHATASE (PAP)
  - 20. PROSTATE-SPECIFIC ANTIGEN (PSA)
  - 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
  - 22. T AND B LYMPHOCYTES
  - 23. TDT
  - 24. THYROGLOBULIN
  - 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)



## 26. BIOCHEMICAL TUMOR MARKERS

**ADA** 

**B-Protein** 

**PNP** 

5'-Nucleotidase

## 27. ONCOGENES

Abl/abl-bcr

AIB1

BCL-2

BRCA1

**CD44** 

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

#### 28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

**ECFR** 

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES



## 30. COLONY STIMULATING FACTORS

#### 31. LYMPHOKINES

Alpha-Interferon

**B Cell Growth Factors** 

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

#### 32. IMMUNOHISTOCHEMICAL STAINS

#### 33. EMERGING TUMOR MARKERS

N-Acetylglucosamine

Actin

Alpha-Actin

**Antineuronal Antibodies** 

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

**CA 50** 

CA 72-4/TAG-72

CA 195

CA-242

CA-549

CAM 26

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

**CTA** 

**CU18** 

**DR-70** 

DU-PAN-2

**Endometrial Bleeding Associated Factor** 

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis



Fibronectin

**FSH** 

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

**HPA** 

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

**KA 93** 

Kinases

**KP16D3** 

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma 552

MABDF3

MAG

ME1

Minactivin

MN/CA9

**MSA** 

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor 1

Myosin

NEA-130

NMP22

OA-519

**Opiod Peptides** 



P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

**SCCL 175** 

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

**SN10** 

Somatostatin

TA-90

**TABA** 

Tachykinin

**TAG 12** 

**TPS** 

Troponin

**Tubulin** 

**VCAM** 

**VEGF** 

Villen

- C. Instrumentation Review And Market Needs
- D. Current and Emerging Technologies
  - 1. MOLECULAR DIAGNOSTICS
    - a. Technology Overview
    - b. Amplification Methods
    - c. Sequencing
    - d. Microarrays/Biochips
  - 2. MONOCLONAL AND POLYCLONAL ANTIBODIES
  - 3. IMMUNOASSAYS
    - a. Technological Principle
    - b. Radioimmunoassay (RIA)
    - c. Enzyme Immunoassays (EIA)

Overview

**ELISA** 

**Immunofiltration** 



## Particle-Membrane Capture Immunoassay

**Enzyme Amplification** 

- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence

Bioluminescence

- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- e. Liposome Flow-Injection Immunoassay
- 4. CHROMOSOME ANALYSIS
  - a. Chronic Myelogenous Leukemia (CML)
  - b. Acute Myeloid Leukemia (AML)
  - c. Acute Lymphoblastic Leukemia (ALL)
  - d. Malignant Lymphomas Lymphoid Malignancies
  - e. Chronic Lymphocytic Leukemia (CLL)
  - f. Solid Cancers
  - g. Chromosomal Translocation and Oncogenes
- 5. ARTIFICIAL INTELLIGENCE
- 6. FLOW CYTOMETRY
- 7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
- 8. BIOSENSORS
- 9. COMPETING/COMPLEMENTING TECHNOLOGIES
  - a. CT
  - b. MRI
  - c. NMR
  - d. PET
  - e. Photonics Spectroscopy
- E. Personal Testing

#### VII. U.S.A.

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales And Market Shares

## **VIII. Competitive Profiles**



Abbott

AdnaGen

Agilent Technologies

Applied Gene Technologies

Arca/Nuvelo

Beckman Coulter/Danaher

**Becton Dickinson** 

**Biomedical Diagnostics** 

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

**Epigenomics** 

Enterix

Enzo Biochem

**Exact Sciences** 

Fujirebio/Innogenetics

**Guided Therapeutics** 

Hologic/Gen-Probe

Kreatech

Kyowa Medex

Mackay Life Sciences

Myriad Genetics

Nanogen Elitech

OncoLab

**Ortho-Clinical Diagnostics** 

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen/Ipsogen

**Quest Diagnostics** 

Radient Pharmaceuticals



Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Thermo Fisher/Life Technologies

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE

Zila

# IX. Appendix: Major Universities and Research

Centers Developing Cancer Diagnostic Technology and Applications



## **List Of Tables**

#### LIST OF TABLES

**Tumor Marker Classification** 

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

EXECUTIVE SUMMARY TABLE: U.S., Total Tumor Marker Test Volume and Sales

Forecast By Market Segment

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates Per 100,000 Population

U.S., Laboratories Performing Tumor Marker Tests by Market Segment

U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.S., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test



#### Volume

- U.S., Physician Office Laboratories Performing Tumor Marker Tests By Practice Size
- U.S., Total Tumor Marker Test Volume Forecast by Market Segment
- U.S., All Market Segments Major Tumor Marker Test Volume Forecast
- U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
- U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
- U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
- U.S., Total Tumor Marker Sales Forecast by Market Segment
- U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
- U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
- U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
- U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CEA Test Volume and Diagnostics Sales by Market Segment
- U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Colon-specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., Cytokeratins Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., Estrogen Receptor Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Interferons Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., Interleukins Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment



- U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Occult Blood Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Total Tumor Marker Sales By Major Supplier
- U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
- U.S., AFP Testing Market Diagnostics Sales by Major Supplier
- U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
- U.S., CEA Testing Market Diagnostics Sales by Major Supplier
- U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
- U.S., HCG Testing Market Diagnostics Sales by Major Supplier
- U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
- U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
- U.S., PAP Testing Market Diagnostics Sales by Major Supplier
- U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
- U.S., PSA Testing Market Diagnostics Sales by Major Supplier



#### I would like to order

Product name: 2016-2020 New Frontiers in the US Cancer Diagnostics Market: Business Challenges,

Emerging Technologies, Competitive Landscape

Product link: https://marketpublishers.com/r/297475E941EEN.html

Price: US\$ 7,840.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/297475E941EEN.html">https://marketpublishers.com/r/297475E941EEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



